Reversal of different drug-resistant phenotypes by an autocatalytic multitarget multiribozyme directed against the transcripts of the ABC transporters MDR1/P-gp, MRP2, and BCRP
Open Access
- 1 April 2005
- journal article
- research article
- Published by Elsevier in Molecular Therapy
- Vol. 11 (4) , 508-522
- https://doi.org/10.1016/j.ymthe.2004.11.016
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Protection of platinum–DNA adduct formation and reversal of cisplatin resistance by anti‐MRP2 hammerhead ribozymes in human cancer cellsInternational Journal of Cancer, 2005
- ABC-transporters: implications on drug resistance from microorganisms to human cancersInternational Journal of Antimicrobial Agents, 2003
- The reversal of multidrug resistance: an updateJournal of Experimental Therapeutics and Oncology, 2003
- Modulation of the atypical multidrug-resistant phenotype by a hammerhead ribozyme directed against the ABC transporter BCRP/MXR/ABCG2Cancer Gene Therapy, 2002
- Selection and characterization of a high-activity ribozyme directed against the antineoplastic drug resistance–associated ABC transporter BCRP/MXR/ABCG2Cancer Gene Therapy, 2001
- Kinetic characterization of ribozymes directed against the cisplatin resistance–associated ABC transporter cMOAT/MRP2/ABCC2Cancer Gene Therapy, 2001
- Ribozyme Structures and MechanismsAnnual Review of Biochemistry, 2000
- Similar cleavage efficiencies of an oligoribonucleotide substrate and an mdr1 mRNA segment by a hammerhead ribozymeGene, 1995
- Reversion of multidrug resistance in the P-glycoprotein-positive human pancreatic cell line (EPP85-181RDB) by introduction of a hammerhead ribozymeBritish Journal of Cancer, 1994
- Simple RNA enzymes with new and highly specific endoribonuclease activitiesNature, 1988